Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06826235

Investigation of the Effect of Date Consumption on Hedonic Hunger and Appetite in Adult Individuals With Type 2 Diabetes

Sponsor: Hacettepe University

View on ClinicalTrials.gov

Summary

The aim of this study was to investigate the effects of date consumption on hedonic hunger and appetite hormones in individuals diagnosed with type 2 diabetes.The main questions it aims to answer are: * Does date consumption reduce hedonic hunger in individuals with type 2 diabetes? * Does persimmon consumption change Ghrelin, GLP-1 and GIP concentrations in individuals with Type 2 diabetes? * Does persimmon consumption reduce HOMA-IR and HbA1c values in individuals with Type 2 diabetes? * Does consumption of persimmon reduce LDL cholesterol, total cholesterol and triglyceride concentrations in individuals with type 2 diabetes? To see the effects of date consumption on hedonic hunger and appetite hormones, the researchers will compare individuals with type 2 diabetes who consume 3 dates daily with individuals with type 2 diabetes who do not. Participants: * Individuals in the intervention group will consume 3 (25 g) Baghdad dates (15 g CHO) daily as part of the breakfast meal, while individuals in the control group will not consume dates. * Three interviews will be conducted with patients. * A record of blood findings and questionnaires will be kept during these interviews.

Official title: Tip 2 Diyabetli Yetişkin Bireylerde Hurma Tüketiminin Hedonik Açlık ve İştah Hormonları Üzerine Etkilerinin İncelenmesi

Key Details

Gender

All

Age Range

19 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-05-14

Completion Date

2025-03-01

Last Updated

2025-02-13

Healthy Volunteers

Conditions

Type 2 Diabetes Mellitus Appetite

Interventions

OTHER

3 dates at the breakfast meal in the diet program

Participants in the intervention group will consume 3 dates at the breakfast meal in the diet program.

Inclusion Criteria: * Individuals diagnosed with Type 2 diabetes aged 19-50 years (excluding menopausal women), * Individuals with BMI between 25-35 kg/m2, * Individuals with a Nutritional Strength Scale score of 2.5 and above, * Individuals who agreed not to start taking new dietary supplements or alternative therapies during the study period, * Individuals who agree not to change their current physical activity level and diet. Exclusion Criteria: * Individuals who do not approve the volunteer consent form, * Individuals with a Nutritional Strength Scale score below 2.5, * Pregnant or breastfeeding women (or women planning to become pregnant within 3 months) * Individuals with dietary energy \<800 kcal/day and \>4000 kcal/day, * Individuals with pre-diabetes, type 1 diabetes and gestational diabetes, * Individuals with HbA1c \>10 * Individuals taking antibiotics or hormone replacement therapy History of malignancy (except non-melanoma skin cancer). * Individuals with regular consumption of dates before inclusion in the study, * Individuals diagnosed with Type 2 diabetes using insulin and oral antidiabetic drugs with thiazolidinedione active substance, * Individuals with a history of diabetic ketoacidosis, diabetic coma or precoma within 6 months prior to the date of admission; serious infections, surgery, serious trauma requiring insulin treatment, haemodialysis treatment (including peritoneal haemodialysis), serious liver injury and serious vascular complications (stroke, myocardial infarction and heart failure) requiring hospitalisation, * Individuals taking pharmacological agents that have effects on appetite such as psychotropics, antiepileptics, antidepressants, antipsychotics and/or steroids, * Individuals diagnosed with eating disorders and/or psychological disorders, * Individuals with physical illnesses that affect eating behaviour or appetite, such as uncontrolled hyperthyroidism or hypothyroidism, Cushing's disease, acromegaly, adrenal insufficiency, chronic renal failure (stage 4 or 5), tuberculosis, human immunodeficiency virus (HIV) infection.

Locations (1)

Erzurum City Hospital

Erzurum, Palandöken, Turkey (Türkiye)